Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program

Defense Health Agency (DHA) · United States government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

October 26, 2026
Response Due
Active
Status

Opportunity Overview

The Department of War (DoW) is required by law (10 U.S.C. � 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics � NA i. Mimrylo - Hematological Agents � NA j. Nuzolvence - Antibiotics � NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices...

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyDefense Health Agency (DHA)
CountryUnited States
CategoryGovernment Procurement
NAICS325412
PSC6505
PublishedOctober 08, 2026
Procurement stageRequest for Proposal (RFP)
Response dueOctober 26, 2026
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedOctober 12, 2026

Source: U.S. Government (SAM.gov) — public domain. GlobalGov is not affiliated with or endorsed by the United States Government.

Related Opportunities in United States

DHA Enterprise-Wide Commercial Solutions Opening (CSO)
Profiling Action And Readiness Tracking Unified System (PARATUS) CSO
Multiple Award Schedule
Multiple Award Schedule
PPVG GEN V Award
Fiscal Year 2027 State Workforce Agency Unemployment Insurance Resource Planning Targets and Guidelines
Advancing Global Health
The Science, Mathematics and Research for Transformation (SMART) Scholarship for Service Program Cooperative Agreement

See every United States Government Procurement opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United States Government Procurement intelligence report in your inbox

A personalized report on United States Government Procurement opportunities, emailed in 5-10 minutes. One per month, no account needed.